Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane® and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC)

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 24, Issue 1, 1999, Pages 69-77

  Rosing, Hilde ^a   Ten Bokkel Huinink, W W ^b   Van Gijn, R ^a   Rombouts, R F M ^c   Bult, A ^d   Beijnen, J H ^a,b  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c Chiron BV   (Netherlands)

^d NONE

Author keywords

Bioequivalence study; Dexrazoxane; Doxorubicin metabolism; ICRF 187

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; RAZOXANE;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

EID: 0033027031     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190013     Document Type: Article

References (24)

1. Hasinoff B.B. (1990) : The hydrolysis activation of the doxorubicin cardioprotective agent ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane)]. Drug Metab. Dispos., 18: 344-349.
2. Speyer J.L., Geen M.D., Kramer E. et al. (1988) : Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N. Engl. J. Med., 319: 745-752.
3. Speyer J.L., Green M.D., Zeleniuch-Jacquotte A. et al. (1992) : ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J. Clin. Oncol., 10: 117-127.
4. ten Bokkel Huinink W.W., Rodenhuis S., Schreuder J.E. et al. (1990) : ICRF-187 protects against doxorubicin induced cardiomyopathy. Ann. Oncol., Suppl 1: 106.
5. Koning J., Palmer P., Franks C.R. et al. (1991) : Cardioxane®/ICRF-187: towards anticancer drug specificity through selective toxicity reduction. Cancer Treat. Rev., 18: 1-19.
6. Bu'lock F.A., Gabriel H.M., Oakhill A., Mott M.G., Martin R.P. (1993) : Cardioprotection by ICRF-187 against high dose anthracycline toxicity in children with malignant disease. Br. Heart J., 70: 185-188.
7. Jelic S., Radulovic S., Nescovic-Konstantinovic Z. et al. (1995) : Cardioprotection with ICRF-187 (Cardioxane®) in patients with advanced breast cancer having cardiac risk factors for doxorubicin cardiotoxicity, treated with the FDC-regimen. Support. Care Cancer, 3: 176-182.
8. Kolaric K., Brandamante V., Cervek J. et al. (1995) : A phase II trial of cardioprotection with Cardioxane® (ICRF-187) in patients with advanced breast cancer receiving 5-fluorouracil, doxorubicin and cyclophosphamide. Oncology, 52: 251-255.
9. Rosing H., van Gijn R., ten Bokkel Huinink W.W., Beijnen J.H. (1997) : High performance liquid chromatographic analysis of the cardioprotective agent dexrazoxane in human plasma and urine. J. Liq. Chrom. Rel. Technol., 20: 583-601.
10. Beijnen J.H., Meenhorst P.L., van Gijn R., Fromme M., Rosing H., Underberg W.J.M. (1991) : HPLC determination of doxorubicin, doxorubicinol and four aglycone metabolites in plasma of AIDS patients. J. Pharm. Biomed. Anal., 9: 995-1002.
11. Proost J.H., Meijer D.K.F. (1992) : MW/PHARM, an integrated software package for drug dosage regimen calculations and therapeutic drug monitoring. Comput. Biol. Med., 22: 155-163.
12. Pidgen A.W. (1992) : Statistical aspects of bioequivalence-a review. Xenobiotica, 22: 881-893.
13. Marzo A., Balant L.P. (1995) : Bioequivalence: an updated reappraisal addressed to applications of interchangeable multi-source pharmaceutical products. Drug Res., 45: 109-115.
14. Pabst G, Jaeger H. (1990) : Review of methods and criteria for the evaluation of bioequivalence studies. Eur. J. Clin. Pharmacol., 38: 5-10.
15. CPMP working party on efficacy of medicinal products (1991) : Note for guidance: investigation of bioavailability and bioequivalence. III/54/89-EN-FINAL.
16. Patnaik R.N., Lesko L.J., Chen M.L., Williams R.L., The FDA Individual Bioequivalence Working Group (1997) : Individual bioequivalence: new concepts in the statistical assessment of bioequivalence metrics. Clin. Pharmacokinet, 33: 1-6.
17. Earhart R.H., Tutsch K.D., Koeller J.M. et al (1982) : Pharmacokinetics of (+)-1,2-di(3,5-dioxopiperazin-1-yl)propane intravenous infusions in adult cancer patients. Cancer Res., 42: 5255-5261.
18. Vogel C.L., Gorowski E., Davila E. et al (1987) : Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC-169780) infusion in patients with solid tumors. Invest. New Drugs, 5: 187-198.
19. Martini A., Moro E., Pacciarini M.A., Tamassia V., Natale N., Piazza E. (1984) : Cross-over study of pharmacokinetics and haematological toxicity of 4′-epi-docorubicin and doxorubicin in cancer patients. Int. J. Clin. Pharm. Res., 4: 231-238.
20. Mross K., Maessen P., van der Vijgh W.J.F., Gall H., Boven E., Pinedo H.M. (1988) : Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J. Clin. Oncol., 6:517-526.
21. Camaggi C.M., Comparsi R., Strocchi E., Testoni F., Angelelli B., Pannuti F. (1988) : Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. Cancer Chemother. Pharmacol., 21: 221-228.
22. Leca F., Marchiset-Leca D., Noble A., Antonetti M. (1991) : New data on the pharmacokinetics of adriamycin and its major metabolite, adriamycinol. Eur. J. Drug Metab. Pharmacokinet, 16: 107-111.
23. Twelves CJ., Dobbs N.A., Aldhous M., Harper P.G., Rubens R.D., Richards M.A. (1991) : Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer. Cancer Chemother. Pharmacol., 28: 302-307.
24. Robert J., Gianni I. (1993) : Pharmacokinetics and meta-bolism of anthracyclines. Cancer Surveys, 17: 219-252.